Evans Syndrome Associated with Primary Immunodeficiency

Evans syndrome (ES) means a person has two or more immune-mediated low blood counts at the same time or one after the other—most often autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP); sometimes immune neutropenia is also present. In AIHA, the immune system wrongly attacks red blood cells, causing anemia. In ITP, it attacks platelets, causing easy bruising and bleeding. ES is a diagnosis of exclusion, which means doctors must rule out other causes of anemia and thrombocytopenia first. A key test is the direct antiglobulin test (DAT/Coombs), which is usually positive in warm-type AIHA. NCBI+2The Blood Project+2

When Evans syndrome is linked to a primary immunodeficiency (PID), the immune system has a built-in regulatory problem caused by genetic variants. These disorders are also called inborn errors of immunity (IEI) or primary immune-regulatory disorders. In these patients, ES often starts earlier, tends to be recurrent or hard to treat, and may come with recurrent infections, enlarged lymph nodes/spleen, or other autoimmune diseases. Studies show that a substantial proportion of children and adults with ES have an underlying IEI when tested with modern genetic panels, so genetic evaluation is recommended in persistent/refractory or early-onset ES. Frontiers+2PMC+2

Evans syndrome (ES) means a person has two or more autoimmune “low blood cell” problems at the same time or one after another—most often autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP); sometimes autoimmune neutropenia joins in. The immune system makes antibodies that wrongly attack red cells and/or platelets (and sometimes neutrophils). When ES happens together with an inborn problem in the immune system (a primary immunodeficiency/inborn error of immunity, IEI), doctors call it ES associated with PID. In these patients, ES tends to start younger, flare more often, last longer, and resist standard medicines. Finding the underlying gene problem matters because targeted treatment (for example, abatacept in CTLA-4/LRBA disorders, or sirolimus for immune dysregulation) can control the disease better than “one-size-fits-all” therapy. Binasss+3Frontiers+3PMC+3

How it happens (very short): in several IEIs (e.g., ALPS; CTLA-4 haploinsufficiency; LRBA deficiency; STAT3 gain-of-function; APDS/PIK3CD; RAG defects), the “brakes” that normally stop immune cells from attacking self are weak. That loss of tolerance lets B-cells and T-cells drive autoantibody-mediated red-cell and platelet destruction, plus chronic lymphoproliferation. Frontiers+2PMC+2

Another names

• Evans syndrome; Evans’ syndrome

• Autoimmune hemolytic anemia (AIHA) with immune thrombocytopenia (ITP)

• Autoimmune cytopenias (multilineage)

• ES secondary to inborn errors of immunity / primary immunodeficiency–associated Evans syndrome (PID-associated ES) Wiley Online Library

In some people, a genetic problem in immune control stops the “brakes” of the immune system from working properly. This loss of immune tolerance allows autoantibodies and mis-programmed immune cells to attack blood cells. Well-described genetic examples include:

• CTLA4 haploinsufficiency and LRBA deficiency (checkpoint pathway defects) → frequent autoimmune cytopenias; often respond to abatacept (a CTLA-4 fusion protein). primaryimmune.org+2Frontiers+2

• ALPS (FAS pathway) → chronic lymph node and spleen enlargement, autoimmune cytopenias. GOSH Hospital site

• APDS (PIK3CD/PIK3R1 variants) → infections + lymphoproliferation + autoimmune cytopenias. NCBI+2PMC+2

• STAT3 gain-of-function → early-onset multi-organ autoimmunity, very often autoimmune cytopenias. PMC+1

• RAG hypomorphic deficiency → immune dysregulation with autoimmune cytopenias (AIHA common). ASH Publications+1

• DADA2 (ADA2 deficiency) → vasculitis/immunodeficiency where Evans-like cytopenias can occur. JAMA Network+1

Types

1. Primary (idiopathic) ES: ES with no clear trigger or underlying disease after careful work-up.

2. Secondary ES: ES that happens because of another condition. Secondary causes include:

   • Primary immunodeficiency / IEI (as above).

   • Systemic autoimmune diseases (e.g., lupus).

   • Chronic infections, malignancies, or drugs (less commonly).
     In recent years, many cases once labeled “idiopathic” have been reclassified as IEI-related after genetic testing. PMC+1

---

Causes

These are conditions or triggers that can lead to ES; many are PIDs (inborn errors of immunity) or immune-regulatory disorders.

1. CTLA4 haploinsufficiency: Fewer CTLA-4 “brakes” on T cells → loss of tolerance → autoimmune cytopenias. Abatacept can replace the missing signal. primaryimmune.org+1

2. LRBA deficiency: LRBA protects CTLA-4; deficiency lowers CTLA-4 levels → ES is common; abatacept may help. Frontiers

3. ALPS (FAS pathway defect): Faulty apoptosis of lymphocytes → lymphoproliferation + autoimmune cytopenias (ES pattern). GOSH Hospital site

4. APDS (PIK3CD/PIK3R1): Overactive PI3Kδ signaling → infections, big nodes/spleen, autoimmune cytopenias including ES. NCBI+1

5. STAT3 gain-of-function: Hyperactive STAT3 drives broad autoimmunity; multilineage cytopenias frequent. PMC

6. RAG deficiency (hypomorphic forms): “Leaky” V(D)J recombination → immune dysregulation; AIHA/ES occur. ASH Publications

7. DADA2 (ADA2 deficiency): Vasculitis + immune dysfunction; autoimmune cytopenias including ES reported. PMC

8. CVID-like disorders: Antibody production defects and immune dysregulation can present with ES. JACI+1

9. CARD11-pathway defects (B cell signaling): Immune dysregulation with autoimmune cytopenias. Frontiers

10. Treg/immune checkpoint pathway disorders (group): Shared mechanism is failed peripheral tolerance → ES. Frontiers

11. Systemic lupus erythematosus (SLE): Autoantibody excess can cause combined AIHA+ITP (secondary ES). Medscape

12. Chronic lymphoproliferation syndromes (non-ALPS): Overactive immune clones can attack blood cells. ASH Publications

13. Chronic infections (as triggers): Some infections can break tolerance and unmask ES in predisposed hosts. Medscape

14. Drug-induced immune dysregulation (rare): Certain drugs can trigger immune cytopenias together. Medscape

15. Post-transplant immune dysregulation: Rarely, immune reconstitution can trigger ES. Medscape

16. Other monogenic IEI (e.g., TPP2, BAFF-R, RASGRP1, etc.): Less common, but reported with autoimmune cytopenias. ASH Publications

17. Immune checkpoint inhibitor exposure (contextual): Over-activation of immunity can cause cytopenias; ES-like pictures reported. ASH Publications

18. Mixed connective tissue or overlap autoimmune disease: Polyautoimmunity increases ES risk. Medscape

19. Castleman disease (rare association): Immune activation can drive multi-lineage cytopenias. Medscape

20. Idiopathic immune dysregulation: When no cause is found, but immune tests suggest tolerance failure. PMC

---

Symptoms

1. Fatigue and weakness from anemia (low red cells).

2. Shortness of breath on exertion due to anemia.

3. Dizziness or rapid heartbeat (the body compensates for low oxygen).

4. Pale or yellow skin (jaundice) from red cell breakdown.

5. Dark urine (hemoglobin breakdown products).

6. Easy bruising or tiny red dots (petechiae) on skin from low platelets.

7. Nosebleeds or bleeding gums (thrombocytopenia).

8. Heavy or prolonged menstrual bleeding in menstruating patients.

9. Enlarged spleen and/or lymph nodes (especially when a PID like ALPS/APDS underlies ES). GOSH Hospital site+1

10. Recurrent infections (clue to an IEI/PID background). NCBI

11. Unexplained fevers (autoimmunity or infection).

12. Weight loss or night sweats (if lymphoproliferation present).

13. Bone pain or abdominal fullness (from enlarged spleen).

14. Headaches or faintness (anemia; rarely bleeding).

15. Relapsing pattern: symptoms come and go as blood counts drop, improve, then drop again—especially in PID-associated ES. Frontiers

---

Diagnostic tests

A) Physical examination

1. General exam for pallor, jaundice, bruises, petechiae: quick bedside clues to anemia or thrombocytopenia. NCBI

2. Spleen and liver size (palpation): enlargement suggests immune dysregulation/lymphoproliferation (e.g., ALPS/APDS). GOSH Hospital site+1

3. Lymph node check: large, persistent nodes can point to ALPS/APDS or other immune dysregulation. GOSH Hospital site

4. Bleeding assessment (oral, nasal, skin, menstrual history): matches platelet count and guides urgency. NCBI

B) “Manual” / bedside tests

5. Vital signs + orthostatic pulse/BP: identify hemodynamic effect of anemia/bleeding.

6. Stool guaiac (occult blood): looks for hidden GI bleeding when platelets are low.

7. Urine check for dark color/hemoglobinuria: supports ongoing hemolysis. Children’s Hospital of Philadelphia

8. Bedside spleen size tracking (serial exams): helps monitor relapse or response.

C) Laboratory & pathological tests

9. Complete blood count (CBC) with differential: documents anemia ± thrombocytopenia (± neutropenia). NCBI

10. Reticulocyte count: shows marrow response; high in hemolysis unless marrow failure co-exists (seen in some IEI like DADA2). The Blood Project+1

11. Hemolysis panel: LDH↑, indirect bilirubin↑, haptoglobin↓ consistent with AIHA. NCBI

12. Direct antiglobulin test (DAT/Coombs): detects antibodies on red cells—key for warm AIHA in ES. NCBI

13. Peripheral blood smear: spherocytes (AIHA); platelet estimate; schistocytes absence helps exclude TTP. Wiley Online Library

14. Autoantibody screens: e.g., ANA if lupus suspected; supports “secondary” ES due to systemic autoimmunity. Medscape

15. Quantitative immunoglobulins and vaccine titers: low Ig or poor responses suggest PID/CVID-like disorders. JACI

16. Lymphocyte subset immunophenotyping (flow cytometry): looks for ALPS/APDS patterns (e.g., double-negative T cells; B/T cell abnormalities). Medscape

17. Genetic testing panel for IEI/immune-regulatory genes: identifies CTLA4, LRBA, PIK3CD/R1, STAT3 GOF, RAG, ADA2, etc.; strongly recommended in persistent/refractory or early-onset ES. PMC+1

D) Electrodiagnostic / physiologic monitoring

Not routine for diagnosing ES itself, but helpful for complications of severe anemia or treatment.

18. Electrocardiogram (ECG): anemia can stress the heart; ECG checks for tachycardia/strain.

19. Pulse oximetry (continuous or spot): monitors oxygenation in symptomatic anemia or active bleeding.

E) Imaging tests

20. Ultrasound of abdomen (± Doppler): measures spleen/liver size and rules out splenic vein issues; painless and repeatable.

21. Chest/neck ultrasound or CT when needed: evaluates lymphadenopathy or infection when PID is suspected. NCBI

22. Echocardiography (when clinically indicated): assesses high-output state from severe chronic anemia.

Non-Pharmacological Treatments (therapies & other measures)

1. Comprehensive diagnostic work-up (include genetic testing). Ask for a PID/IEI gene panel when cytopenias are chronic, severe, refractory, or come with lymphoproliferation or unusual infections. A molecular diagnosis guides targeted therapy (e.g., abatacept in CTLA4/LRBA, leniolisib in APDS) and can prevent delays or risky surgeries. PMC+1

2. Vaccination review (avoid live vaccines if significant PID). Keep inactivated vaccines (influenza, pneumococcal, COVID-19) up to date; avoid live vaccines if the IEI or therapy (e.g., rituximab) makes them unsafe. This reduces severe infections that can trigger flares. Jaci In Practice+1

3. Infection prevention & early treatment plan. Teach strict hand hygiene, prompt fever evaluation, and low threshold for cultures/antibiotics; infections often precipitate hemolysis or thrombocytopenia. Provide a written action plan. PMC+1

4. Transfusion support with precautions. For severe anemia or bleeding, use phenotype-matched, leukocyte-reduced, irradiated blood products; alert the blood bank about warm autoantibodies to minimize delays. PMC

5. Folate support & hemolysis care (non-drug). Ensure adequate folate intake because hemolysis increases needs; monitor bilirubin and hemoglobin; consider hydration and rest during hemolytic flares. PMC

6. Bone health protection during/after steroids. Counsel weight-bearing exercise, calcium/vitamin D intake, and fracture prevention; steroids raise fracture risk even with short courses. ASH Publications

7. Thrombosis risk reduction. Evans syndrome (especially with hemolysis) carries higher clot risk; advise staying mobile, hydration, and urgent care for limb swelling or chest pain; clinicians assess for anticoagulation when platelets allow. The Lancet

8. Bleeding-safety plan. Use a soft toothbrush, avoid high-risk contact sports, and seek help for black stools, nosebleeds >20 minutes, or new bruising/petechiae. Keep platelet targets individualized. American Society of Hematology

9. Dental and oral care. Regular dental care reduces gum bleeding and infection sources; treat mouth ulcers promptly in neutropenia. NCBI

10. Nutrition counseling. Aim for balanced protein/iron-rich foods (only supplement iron if lab-proven deficiency), limit alcohol, and keep hydration; malnutrition worsens fatigue and recovery. NCBI

11. Activity pacing & fatigue management. Gentle daily activity helps stamina without overexertion during low counts; plan rest around procedures or infusions. NCBI

12. Sun/skin care with steroids & immunosuppression. Use sunscreen and skin checks; immunosuppression raises skin infection and lesion risks. ASH Publications

13. Psychosocial support. Chronic relapsing illness affects mood and family stress; brief counseling and peer support improve adherence and quality of life. Haematologica

14. Medication safety education. Avoid NSAIDs/aspirin when platelets are low; always check drug interactions when on immunosuppressants. American Society of Hematology

15. Pregnancy & fertility counseling. Plan pregnancies; some drugs are unsafe (e.g., mycophenolate). TPO-RAs and IVIG have specific considerations. PMC

16. Peri-procedure planning. Coordinate with hematology for safe platelet/hemoglobin thresholds before dental/surgical procedures and for stress-dose steroid plans if needed. American Society of Hematology

17. Home monitoring. Keep a simple log of symptoms (fatigue, bruising, jaundice, fevers), clinic counts, and medication changes to spot early relapses. NCBI

18. Allergy & infusion reaction readiness. Educate about IVIG/rituximab infusion reactions and when to seek help. Medscape

19. Specialist team care. Combine hematology + clinical immunology for ES-PID; this improves selection of targeted treatments and testing. PMC

20. Patient education materials. Provide easy resources (GARD/NORD) explaining Evans syndrome and PID to support shared decisions. GARD Information Center+1

---

Drug Treatments

Important: Doses are typical references for adults; clinicians individualize for age, weight, organ function, pregnancy, drug interactions, and the specific IEI.

1. Prednisone / Prednisolone (corticosteroid). Dose: ~1–1.5 mg/kg/day for 2–4 weeks, then taper. Timing/Purpose: First-line to quickly control hemolysis and raise platelets. Mechanism: Broad immunosuppression—reduces autoantibodies and macrophage-mediated cell destruction. Side-effects: High sugars, mood changes, infection risk, bone loss, weight gain; taper slowly to prevent relapse. PMC+1

2. Dexamethasone (steroid pulse). Dose: 40 mg daily × 4 days; cycles may repeat. Timing/Purpose: Rapid ITP rescue; sometimes combined with other agents. Mechanism: Potent steroid burst dampening autoimmunity. Side-effects: Insomnia, mood swings, hyperglycemia; avoid prolonged use. American Society of Hematology

3. Intravenous immunoglobulin, IVIG (immunomodulator). Dose: 1 g/kg/day for 1–2 days (or 0.4 g/kg × 5 days). Timing/Purpose: Quick platelet rise or steroid-sparing; helpful in bleeding or peri-procedure. Mechanism: Saturates Fc receptors and modulates autoantibodies to reduce destruction. Side-effects: Headache, aseptic meningitis, thrombosis risk in predisposed patients. PMC+1

4. Rituximab (anti-CD20). Dose: 375 mg/m² weekly × 4 (common schedule). Timing/Purpose: Second-line for steroid-refractory AIHA/ITP and widely used in Evans syndrome. Mechanism: Depletes B-cells producing autoantibodies. Side-effects: Infusion reactions, infections, HBV reactivation; may impair vaccine responses. PMC

5. Sirolimus / Rapamycin (mTOR inhibitor). Dose: often 2–2.5 mg/m² daily (target trough ~5–15 ng/mL). Timing/Purpose: Steroid-sparing in refractory autoimmune cytopenias, especially in immune-dysregulation syndromes (e.g., ALPS). Mechanism: T-cell regulation via mTOR blockade; reduces lymphoproliferation and autoimmunity. Side-effects: Mouth ulcers, high lipids, cytopenias, infections. PMC+1

6. Mycophenolate mofetil (antimetabolite). Dose: start 500 mg BID → titrate to 1 g BID as tolerated. Timing/Purpose: Steroid-sparing maintenance for AIHA/ITP; useful in mixed autoimmune features. Mechanism: Inhibits lymphocyte IMPDH → limits B/T-cell proliferation. Side-effects: GI upset, cytopenias, teratogenic; contraception needed. New England Journal of Medicine+1

7. Azathioprine (antimetabolite). Dose: ~1–2(–3) mg/kg/day; check TPMT level first. Timing/Purpose: Older steroid-sparing option for chronic AIHA/ITP. Mechanism: Purine analog suppressing lymphocyte proliferation. Side-effects: Myelosuppression, liver toxicity, infections; slow onset (weeks). nssg.oxford-haematology.org.uk+1

8. Cyclosporine (calcineurin inhibitor). Dose: ~2.5 mg/kg BID initially, adjust by levels/response. Timing/Purpose: Refractory AIHA/ITP when others fail. Mechanism: Blocks T-cell activation (IL-2). Side-effects: Kidney toxicity, hypertension, tremor, gum hyperplasia. legeforeningen.no

9. Cyclophosphamide (alkylator). Dose: low-dose oral 1–2 mg/kg/day or IV pulses in select refractory cases. Timing/Purpose: Rescue in highly refractory disease. Mechanism: Broad B/T-cell cytotoxicity. Side-effects: Myelosuppression, infertility risk, bladder toxicity; use sparingly. PMC

10. Thrombopoietin receptor agonists (TPO-RA)—Romiplostim. Dose: start 1 mcg/kg SC weekly; titrate to goal platelets 50–200×10⁹/L (max 10 mcg/kg). Timing/Purpose: Chronic ITP component of ES when bleeding risk persists. Mechanism: Stimulates megakaryocytes to produce platelets. Side-effects: Headache, thrombosis risk; monitor counts. pi.amgen.com+1

11. TPO-RA—Eltrombopag. Dose: start 50 mg daily (25 mg in many Asian patients or liver disease); adjust every ~2 weeks to platelet target. Timing/Purpose: Chronic ITP in ES; oral option. Mechanism: TPO-R agonist increasing platelet production. Side-effects: Liver enzyme rise, cataracts (long term), thrombosis risk. Novartis+1

12. Fostamatinib (SYK inhibitor). Dose: 100 mg BID; may increase to 150 mg BID if inadequate response after 4 weeks. Timing/Purpose: Later-line for ITP, including Evans variants, especially if thrombosis history limits TPO-RAs. Mechanism: Inhibits Fc-mediated platelet destruction. Side-effects: Diarrhea, hypertension, liver enzyme elevation. U.S. Food and Drug Administration+1

13. Abatacept (CTLA4-Ig). Dose: IV or SC regimens vary; commonly weight-based IV monthly or SC weekly (doses individualized). Timing/Purpose: Targeted therapy for CTLA4 or LRBA deficiency with autoimmune cytopenias. Mechanism: Restores inhibitory costimulation (blocks CD80/86–CD28), calming overactive T-cells. Side-effects: Infections; check TB/hepatitis status. PMC+1

14. Leniolisib (PI3Kδ inhibitor). Dose: 70 mg twice daily (≥45 kg) for APDS. Timing/Purpose: Targeted therapy when Evans-like cytopenias occur with APDS (PIK3CD/PIK3R1). Mechanism: Inhibits hyperactive PI3Kδ pathway → normalizes immune subsets and reduces dysregulation. Side-effects: Infections (sinusitis), dermatitis; monitor labs. NCBI+1

15. IV anti-D (RhIG) – selected Rh-positive patients. Dose: e.g., 50–75 µg/kg once (specialist use). Timing/Purpose: Rapid ITP rescue if Rh-positive and spleen intact; less used in PID. Mechanism: Competes for splenic clearance. Side-effects: Hemolysis risk; avoid in anemia. ASH Publications

16. G-CSF (filgrastim). Dose: common starting 5 mcg/kg SC daily for autoimmune/cyclic neutropenia; titrate to ANC and symptoms. Timing/Purpose: Raises neutrophils to prevent infections in AIN. Mechanism: Stimulates granulopoiesis. Side-effects: Bone pain, splenomegaly; rare thrombosis. Medscape+1

17. Mycophenolic acid delayed-release (enteric). Dose: equivalent total daily dose to MMF (often 720 mg BID). Purpose/Mechanism/SE: As in #6; GI-friendlier formulation. Mayo Clinic

18. Cyclosporine-A (alternative schedules). Dose: per consensus, typical initial ~2.5 mg/kg BID; trough-guided. Purpose/Mechanism/SE: See #8. legeforeningen.no

19. Methylprednisolone IV pulse. Dose: 500–1000 mg/day × 3 days for severe flare (then oral taper). Purpose: Emergency control of life-threatening hemolysis or bleeding. SE: As with steroids; monitor glucose/pressure. PubMed

20. Second TPO-RA switch or combination strategy. Dose: switch romiplostim ↔ eltrombopag per labeling if inadequate response; sometimes combined short-term with other agents under specialist care. Purpose/Mechanism/SE: As in #10–11. PubMed

---

Dietary Molecular Supplements

1. Folate. Hemolysis raises folate needs; food sources (leafy greens/beans) help, and supplements can prevent megaloblastic changes when hemolysis is active. Avoid mega-doses without testing. PMC

2. Vitamin B12. Check and replace if low—B12 deficiency worsens anemia and fatigue. Oversupplementing without deficiency is unnecessary. NCBI

3. Vitamin D. Supports bone health during steroids and may modulate immunity modestly; dose per level (often 800–2000 IU/day). ASH Publications

4. Calcium. Combine with vitamin D for steroid-related bone protection if dietary intake is low. ASH Publications

5. Omega-3 fatty acids. May modestly lower inflammation; choose food sources (fish, nuts) first; avoid high-dose capsules if bleeding risk is high. NCBI

6. Zinc (only if deficient). Correcting deficiency can support immune function; excess zinc can lower copper and cause cytopenias—test first. NCBI

7. Iron (only if deficiency proven). Do not give iron for hemolysis unless iron deficiency is confirmed by labs (ferritin, iron, TSAT). Hemolysis alone doesn’t mean iron deficiency. NCBI

8. Probiotics—avoid in significant PID. In moderate–severe PID or central lines, live probiotics may be risky; ask your immunologist first. Jaci In Practice

9. Multivitamin (standard doses). Can cover mild dietary gaps; avoid high-dose fat-soluble vitamins. NCBI

10. Caffeine moderation & hydration. Adequate fluids support well-being during hemolysis and help avoid headaches during IVIG days. Medscape

---

Immunity-booster / Regenerative / Stem-cell–related Drugs

1. Filgrastim (G-CSF). Dose: ~5 mcg/kg SC daily (adjust). Function/Mechanism: Stimulates bone marrow to make neutrophils; lowers infection risk in autoimmune neutropenia. Medscape

2. Romiplostim (TPO-RA). Dose: start 1 mcg/kg SC weekly, titrate. Function/Mechanism: Regenerates platelet production by activating c-Mpl receptor. pi.amgen.com

3. Eltrombopag (TPO-RA). Dose: usually 50 mg daily (25 mg in many Asian patients). Function/Mechanism: Oral stimulator of megakaryopoiesis to improve platelets. Novartis

4. Epoetin alfa / darbepoetin (ESAs) – selected cases. Dose: per anemia protocols. Function/Mechanism: Stimulates red-cell production when anemia has a hypoproliferative component (not for active hemolysis spikes). PMC

5. IVIG (immunomodulatory). Dose: 1 g/kg/day ×1–2 days for rescue. Function/Mechanism: Fc receptor blockade reduces immune destruction—functional “immune reset” during flares. PMC

6. Targeted immune pathway agents (disease-specific): Abatacept for CTLA4/LRBA defects; Leniolisib for APDS. Dose: per labeling/trials. Function/Mechanism: Correct upstream pathway abnormalities to restore immune balance, indirectly normalizing counts. PMC+1

---

Surgeries / Procedures

1. Allogeneic hematopoietic stem-cell transplantation (HSCT). Why: Potentially curative for select severe IEIs causing ES (e.g., profound immune dysregulation unresponsive to targeted therapy). Requires transplant-center evaluation and careful risk-benefit discussion. Astct Journal

2. Splenectomy (laparoscopic). Why: Historically used for refractory AIHA/ITP; now less favored in PID due to lifelong infection risk. Consider only after gene-informed options fail and with lifelong infection prophylaxis. Haematologica

3. Central venous access device placement. Why: For frequent infusions (IVIG, transfusions) in difficult access. Infection prevention protocols are essential in PID. PMC

4. Cholecystectomy. Why: Pigment gallstones can occur after years of hemolysis; remove gallbladder if symptomatic stones or complications develop. PMC

5. Splenic artery embolization (rare). Why: As a less invasive alternative to splenectomy in selected bleeding crises—specialist decision only. The Lancet

---

Preventions

1. Keep vaccines updated (inactivated) and avoid live vaccines if your IEI or medicines make them unsafe. Jaci In Practice

2. Hand hygiene; rapid evaluation of fevers and infections. PMC

3. Avoid NSAIDs/aspirin during thrombocytopenia unless prescribed. American Society of Hematology

4. Use a soft toothbrush and electric shaver to limit bleeding. American Society of Hematology

5. Plan pregnancy and medicines ahead of time. PMC

6. Keep a medication/allergy card and blood bank alert for warm autoantibodies. PMC

7. Bone health: vitamin D/calcium intake and activity during steroid therapy. ASH Publications

8. Stay mobile and hydrated on travel/illness days (clot prevention). The Lancet

9. Coordinate procedures with hematology for safe count thresholds. American Society of Hematology

10. Regular specialist follow-up with hematology + immunology teams. PMC

---

When to see doctors urgently

Call or go to emergency care for any of these: new or heavy bleeding (nose/gums, black stools), sudden yellowing or dark urine suggesting hemolysis, fever ≥38 °C or chills (especially if neutropenic), chest pain/shortness of breath or one-sided leg swelling (possible blood clot), severe headache/vision change, or confusion. Early care prevents severe complications. NCBI+1

---

What to eat” and “what to avoid”

Eat: (1) balanced meals with lean protein and leafy greens (folate); (2) iron-rich foods only if labs show iron deficiency; (3) fruits/vegetables for vitamins; (4) dairy or fortified alternatives for calcium + vitamin D; (5) fish, nuts, seeds for omega-3s; (6) plenty of water, especially around infusions; (7) small, frequent meals on steroid days; (8) whole grains for steady energy; (9) cooked—not raw—animal products to reduce infection risk; (10) foods gentle on the stomach if you take steroids (e.g., yogurt, bananas). ASH Publications+1

Avoid/limit: alcohol (worsens bleeding/falls), herbal “immune boosters” that may stimulate autoimmunity, high-dose omega-3s if bleeding, raw eggs/meat/shellfish in significant PID, and unnecessary iron if not iron-deficient. Always check supplement-drug interactions. Jaci In Practice

---

Frequently Asked Questions

1) Is Evans syndrome the same as “immune pancytopenia”?
It’s a form of immune cytopenias involving at least two lineages (usually AIHA + ITP) and sometimes neutropenia; counts can fluctuate over time. Orpha

2) Why test for a gene cause?
Because ~half of persistent/refractory cases have an IEI; a genetic answer opens targeted options and improves long-term planning. PMC

3) Do I always need steroids?
Steroids are common first-line and often work fast, but the goal is to reduce or stop them using other medicines that are safer long term. ASH Publications

4) Is rituximab safe?
It’s effective in many patients but can increase infection risk and block some vaccine responses; doctors screen and pre-medicate before infusions. PMC

5) Are TPO-RAs “blood thickeners”?
They increase platelet production, not blood thickness. We aim for safe platelet ranges (≥50×10⁹/L) and watch for clots. pi.amgen.com+1

6) What if I have STAT3-GOF, CTLA4, LRBA, or APDS?
Targeted agents (e.g., abatacept for CTLA4/LRBA; leniolisib for APDS) can calm the root problem and help cytopenias. PMC+1

7) Is splenectomy still done?
Much less often—especially in PID—because of lifelong infection risk; it’s a late option only if safer therapies fail. Haematologica

8) Can ES-PID go into remission?
Yes, but relapses are common; ongoing follow-up is key, and outcomes improve with gene-informed care. Haematologica

9) Are live probiotics okay?
Often not recommended in significant PID or with central lines due to infection risk—ask your immunologist. Jaci In Practice

10) Can I travel?
Yes—carry a summary, recent labs, meds, and a plan for fevers/bleeding; stay hydrated and mobile on long trips. The Lancet

11) What about pregnancy?
Plan with hematology and maternal-fetal medicine; switch away from teratogens (e.g., mycophenolate) and map safe options. PMC

12) How fast do medicines work?
IVIG and steroid pulses can help in days; rituximab and steroid-sparing drugs may take weeks; TPO-RAs often respond within 1–2 weeks. Annals of Blood

13) Do I need antibiotic prophylaxis?
Sometimes—especially after splenectomy or in certain IEIs—your team may use prophylaxis and emergency antibiotics for fever. Jaci In Practice

14) Is HSCT a cure?
For some IEIs, HSCT can be curative; it carries risks and is considered after careful multi-specialty review. Astct Journal

15) Where can I read more in simple language?
See GARD and NORD for plain explanations and support links. GARD Information Center+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 29, 2025.